Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.

Abstract

Five patients receiving increased dose or frequency of pamidronate beyond the recommended dose (90 mg/monthly) exhibited nephrotic proteinuria (range 3.96-24 g/24 h). On dose reduction or discontinuation, three of these patients showed decreased proteinuria to normal levels (< 1 g/24 h), and proteinuria decreased to 4.5 g/24 h from a peak of 24 g/24 h in one patient. One patient on haemodialysis (hence not evaluable) had proteinuria of 2 g/24 h and elevated creatinine levels. One other patient continued to show elevated creatinine levels (272.8 micro mol/l). Renal biopsies obtained in two patients revealed focal segmental glomerulosclerosis.

• Authors: Raman Desikan, Yuliya Veksler, Syed Raza, Barry Stokes, Tariq Sabir, Zu Jun Li, Sundar Jagannath
• Journal: British journal of haematology (Br J Haematol) Vol. 119 Issue 2 Pg. 496-9 (Nov 2002) ISSN: 0007-1048 [Print] England
• PMID: 12406092 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Diphosphonates
• Bence Jones Protein
• Creatinine
• Pamidronate

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Bence Jones Protein (urine)
• Creatinine (urine)
• Diphosphonates (adverse effects, therapeutic use)
• Drug Administration Schedule
• Female
• Humans
• Kidney Glomerulus (drug effects)
• Male
• Middle Aged
• Multiple Myeloma (drug therapy, urine)
• Pamidronate
• Proteinuria (chemically induced)